A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.

Lenvatinib (LENVA) is an oral antineoplastic drug used for the treatment of hepatocellular carcinoma and thyroid carcinoma. LENVA therapeutic drug monitoring (TDM) should be mandatory for a precision medicine to optimize the drug dosage. To this end, the development of a sensitive and robust quantif...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Martina Zanchetta, Valentina Iacuzzi, Bianca Posocco, Giorgia Bortolin, Ariana Soledad Poetto, Marco Orleni, Giovanni Canil, Michela Guardascione, Luisa Foltran, Valentina Fanotto, Fabio Puglisi, Sara Gagno, Giuseppe Toffoli
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/b7f52d55ed6e42d188d408f4a394726d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b7f52d55ed6e42d188d408f4a394726d
record_format dspace
spelling oai:doaj.org-article:b7f52d55ed6e42d188d408f4a394726d2021-12-02T20:13:28ZA rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.1932-620310.1371/journal.pone.0259137https://doaj.org/article/b7f52d55ed6e42d188d408f4a394726d2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259137https://doaj.org/toc/1932-6203Lenvatinib (LENVA) is an oral antineoplastic drug used for the treatment of hepatocellular carcinoma and thyroid carcinoma. LENVA therapeutic drug monitoring (TDM) should be mandatory for a precision medicine to optimize the drug dosage. To this end, the development of a sensitive and robust quantification method to be applied in the clinical setting is essential. The aim of this work was to develop and validate a sensitive, rapid, and cost-effective LC-MS/MS method for the quantification of LENVA in human plasma. On this premise, sample preparation was based on a protein precipitation and the chromatographic separation was achieved on a Synergi Fusion RP C18 column in 4 min. The method was completely and successfully validated according to European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines, with good linearity in the range of 0.50-2000 ng/mL (R≥0.9968). Coefficient of variation (CV) for intra- and inter-day precision was ≤11.3% and accuracy ranged from 96.3 to 109.0%, internal standard normalized matrix effect CV% was ≤2.8% and recovery was ≥95.6%. Successful results were obtained for sensitivity (signal to noise (S/N) ratio >21) and selectivity, dilution integrity (CV% ≤ 4.0% and accuracy 99.9-102%), and analyte stability under various handling and storage conditions both in matrix and solvents. This method was applied to quantify LENVA in patient's plasma samples and covered the concentration range achievable in patients. In conclusion, a sensitive and robust quantification method was developed and validated to be applied in the clinical setting.Martina ZanchettaValentina IacuzziBianca PosoccoGiorgia BortolinAriana Soledad PoettoMarco OrleniGiovanni CanilMichela GuardascioneLuisa FoltranValentina FanottoFabio PuglisiSara GagnoGiuseppe ToffoliPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0259137 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Martina Zanchetta
Valentina Iacuzzi
Bianca Posocco
Giorgia Bortolin
Ariana Soledad Poetto
Marco Orleni
Giovanni Canil
Michela Guardascione
Luisa Foltran
Valentina Fanotto
Fabio Puglisi
Sara Gagno
Giuseppe Toffoli
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
description Lenvatinib (LENVA) is an oral antineoplastic drug used for the treatment of hepatocellular carcinoma and thyroid carcinoma. LENVA therapeutic drug monitoring (TDM) should be mandatory for a precision medicine to optimize the drug dosage. To this end, the development of a sensitive and robust quantification method to be applied in the clinical setting is essential. The aim of this work was to develop and validate a sensitive, rapid, and cost-effective LC-MS/MS method for the quantification of LENVA in human plasma. On this premise, sample preparation was based on a protein precipitation and the chromatographic separation was achieved on a Synergi Fusion RP C18 column in 4 min. The method was completely and successfully validated according to European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines, with good linearity in the range of 0.50-2000 ng/mL (R≥0.9968). Coefficient of variation (CV) for intra- and inter-day precision was ≤11.3% and accuracy ranged from 96.3 to 109.0%, internal standard normalized matrix effect CV% was ≤2.8% and recovery was ≥95.6%. Successful results were obtained for sensitivity (signal to noise (S/N) ratio >21) and selectivity, dilution integrity (CV% ≤ 4.0% and accuracy 99.9-102%), and analyte stability under various handling and storage conditions both in matrix and solvents. This method was applied to quantify LENVA in patient's plasma samples and covered the concentration range achievable in patients. In conclusion, a sensitive and robust quantification method was developed and validated to be applied in the clinical setting.
format article
author Martina Zanchetta
Valentina Iacuzzi
Bianca Posocco
Giorgia Bortolin
Ariana Soledad Poetto
Marco Orleni
Giovanni Canil
Michela Guardascione
Luisa Foltran
Valentina Fanotto
Fabio Puglisi
Sara Gagno
Giuseppe Toffoli
author_facet Martina Zanchetta
Valentina Iacuzzi
Bianca Posocco
Giorgia Bortolin
Ariana Soledad Poetto
Marco Orleni
Giovanni Canil
Michela Guardascione
Luisa Foltran
Valentina Fanotto
Fabio Puglisi
Sara Gagno
Giuseppe Toffoli
author_sort Martina Zanchetta
title A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
title_short A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
title_full A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
title_fullStr A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
title_full_unstemmed A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
title_sort rapid, simple and sensitive lc-ms/ms method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/b7f52d55ed6e42d188d408f4a394726d
work_keys_str_mv AT martinazanchetta arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT valentinaiacuzzi arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT biancaposocco arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT giorgiabortolin arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT arianasoledadpoetto arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT marcoorleni arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT giovannicanil arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT michelaguardascione arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT luisafoltran arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT valentinafanotto arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT fabiopuglisi arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT saragagno arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT giuseppetoffoli arapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT martinazanchetta rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT valentinaiacuzzi rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT biancaposocco rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT giorgiabortolin rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT arianasoledadpoetto rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT marcoorleni rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT giovannicanil rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT michelaguardascione rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT luisafoltran rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT valentinafanotto rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT fabiopuglisi rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT saragagno rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
AT giuseppetoffoli rapidsimpleandsensitivelcmsmsmethodforlenvatinibquantificationinhumanplasmafortherapeuticdrugmonitoring
_version_ 1718374787011575808